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Abstract
Background: Hepatobiliary and pancreatic (HPB) operations have a high incidence of post-operative
nosocomial infections. The aim of the present study was to determine whether hospitalization up to
1 year before HPB surgery is associated with an increased risk of post-operative infection, surgical-site
infection (SSI) and infection resistant to surgical chemoprophylaxis.
Methods: A retrospective cohort study of patients undergoing HPB surgeries between January 2008
and June 2013 was conducted. A multivariable logistic regression model was used for controlling for
potential confounders to determine the association between pre-operative admission and post-opera-
tive infection.
Results: Of the 1384 patients who met eligibility criteria, 127 (9.18%) experienced a post-operative
infection. Pre-operative hospitalization was independently associated with an increased risk of a post-
operative infection [adjusted odds ratio (aOR): 1.61, 95% confidence interval [CI]: 1.06–2.46] and SSI
(aOR: 1.79, 95% CI: 1.07–2.97). Pre-operative hospitalization was also associated with an increased
risk of post-operative infections resistant to standard pre-operative antibiotics (OR: 2.64, 95%
CI: 1.06–6.59) and an increased risk of resistant SSIs (OR: 3.99, 95% CI: 1.25–12.73).
Discussion: Pre-operative hospitalization is associated with an increased incidence of post-operative
infections, often with organisms that are resistant to surgical chemoprophylaxis. Patients hospitalized
up to 1 year before HPB surgery may benefit from extended spectrum chemoprophylaxis.
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Introduction
Hepatobiliary and pancreatic (HPB) resections are complex
operations associated with a high incidence of post-operative
morbidity. Post-operative infections constitute the largest pro-
portion of post-operative morbidity and are strongly associated
with long-term oncological outcomes, including the time to
initiation of chemotherapy, recurrence and overall survival.1–3
Post-operative infections also impose a considerable financial
burden to both hospital and patient by increasing the hospital
length of stay, utilization of resources and readmission rates.4
Development of a surgical-site infection (SSI) can extend the
duration of hospitalization by up to 10.6 days and cost an
additional $20 842.5,6 Collectively, post-operative infections
impose considerable and potentially preventable costs exceed-
ing $900 million and hospital readmissions accounting for an
additional $700 million in healthcare expenditures.5,7
Prior hospitalization may place patients at a higher risk of
colonization with hospital-associated organisms that could lead
to post-operative infection after HPB surgery. Prior hospital-
ization is associated with increased incidence of resistant hospi-
tal-associated infections and Clostridium difficile colonization
among patients admitted to surgical and non-surgical wards.8,9
Furthermore, patients colonized with one resistant pathogen
are frequently colonized with other resistant organisms;
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methicillin-resistant Staphylococcus aureus (MRSA), van-
comycin-resistant Enterococcus (VRE) and other multi-drug
resistant organisms have been reported.10–12
Many patients undergoing HPB surgery are admitted to
the hospital prior to surgery for diagnostic testing or thera-
peutic interventions. Regardless of pre-operative hospitaliza-
tion status, these patients receive standard peri-operative
prophylaxis. However, these drugs possess antimicrobial
spectra that may fail to protect against these resistant, hospi-
tal-acquired pathogens. In this study, it is hypothesized that a
prior hospital admission increases the risk of a post-operative
infection in patients undergoing HPB surgery. It is also
hypothesized that patients sustaining infections are infected
with microorganisms that are resistant to peri-operative
antimicrobial prophylaxis.
Patients and methods
Study design and patient selection
We conducted a retrospective cohort study of all adult patients
(≥18 years) who underwent HPB surgery at the University of
Pittsburgh Medical Center between 1 January 2008 and 1 July
2013. These surgeries include: minor and major liver resec-
tions; bile duct reconstructions/resections; central and distal
pancreatectomies; pancreaticoduodenectomies; pancreatic enu-
cleations; and liver radiofrequency ablations. Data for each sur-
gery had been prospectively collected for an institutional
clinical registry. To ensure accuracy, registry data were cross-
referenced with operating room logs. Patients who previously
underwent organ transplantation or had multiple HPB surg-
eries were excluded. Those without post-operative infections
who did not survive to post-operative day 30 were also
excluded.
Our primary exposure of interest was pre-operative hospital-
ization, which was defined as any hospital admission occurring
up to 1 year prior to the index operative admission based on
other studies that identified prior hospitalizations up to 1 year
as a risk factor for carriage of resistant organisms and as a risk
factor for being admitted with a resistant infection.8,13–15 The
present primary outcome of interest was post-operative infec-
tion within 30 days of surgery as defined by Centers for
Disease Control’s (CDC) standardized definitions of HAIs and
SSIs: ‘localized or systemic condition[s]’ resulting from an ‘ad-
verse reaction to the presence of an infectious agent(s)’ that
did not exist at the time of surgery occurring ‘within 30 days’
of the operative procedure.16,17 Patients with post-operative
infections were identified from institutional data previously
submitted to the National Nosocomial Infections Surveillance
database: an ongoing collaborative surveillance system spon-
sored by the CDC.18 Using these data, we abstracted microbi-
ology information, including the type of infection
(bloodstream infection, gastrointestinal, lower respiratory
infection, pneumonia, SSI, skin and soft tissue, and urinary
tract infection), species of organism and antibiotic sensitivity.
Because risk factors for post-operative HAIs, in general, differ
from those of SSIs specifically, we analysed each outcome sepa-
rately.19
Patient demographic information and peri-operative factors
known to influence the risk of post-operative infection were
also collected. These included: age, race, smoking status, body
mass index, malignancy, diabetes, American Society of Anes-
thesiologists (ASA) physical status, surgical chemoprophylaxis
data (type, timing and dose), operative time, blood loss during
surgery, an intra-operative red blood cell transfusion and open
versus minimally invasive surgery.7,20–30
Statistical analysis
Bivariate analyses of the association between each variable and
exposure to pre-operative hospitalization using the Student’s t,
Pearson v2, and Wilcoxon’s rank-sum tests as appropriate were
performed. We used univariable logistic regression to calculate
unadjusted odds ratios (OR) and 95% confidence intervals
(CI) for the association between pre-operative hospitalization
and the risk of HAIs and SSIs in particular. Variables with
P-values below 0.2 in univariable analyses were included in a
final multivariable model to estimate an adjusted OR (aOR)
and 95% CI for the association between pre-operative hospital-
ization and the risk of post-operative infection. For the sub-
group of patients with infections, rates of infection with
resistant organisms were compared between those with and
without a pre-operative hospitalization using the Pearson v2
and Fisher’s exact tests. We also assessed collinearity using
variance inflation factors, evaluated all potential interactions
and used the Hosmer–Lemeshow test to assess goodness of fit
for the final multivariable models. All analyses were conducted
in Stata 13 (StataCorp, College Station, TX, USA). P-values
< 0.05 were considered statistically significant.
Results
Patient demographics and characteristics
We identified 1521 adult patients who underwent HPB surgery
during the period of study. We excluded patients who had
more than one surgery (n = 90), patients without HAIs who
died before post-operative day 30 (n = 4) and those missing
variables of interest (n = 13). Of the 90 patients excluded for
having multiple surgeries, five patients experienced an infection
after the second surgery, which was within several months after
the first surgery in each case. Our final analysis included 1384
patients meeting both inclusion and exclusion criteria. Of this
cohort, 298 (21.5%) had at least one pre-operative hospitaliza-
tion. Compared with patients who were not hospitalized pre-
operatively, these patients were more often diabetic, had a
worse ASA status, longer operative times, increased operative
blood loss, a greater likelihood of intra-operative blood trans-
fusions, a different surgical chemoprophylaxis profile and less
frequent intra-operative re-dosing of surgical chemoprophy-
laxis in cases where this was indicated (Table 1).
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Risk of overall infection
Post-operative infection occurred in 127 patients (9.2%); of
these, 43 occurred in patients who were hospitalized pre-
operatively (14.4%) and 84 occurred in patients who were
not hospitalized in the year before surgery (7.7%, P < 0.001)
(Table 1). Patients who experienced a post-operative infec-
tion were more likely to be older, male patients undergoing
open surgery for cancer, to experience longer operative times
and increased operative blood loss, to have a different
surgical antibiotic prophylaxis profile and less frequent intra-
operative re-dosing of surgical chemoprophylaxis in cases
where this was indicated. Pre-operative hospitalization was
associated with a significantly increased risk of post-operative
infection (unadjusted OR 2.01, 95% CI: 1.36–2.98) (Table 2).
After adjusting for other covariates, pre-operative hospitaliza-
tion was significantly associated with an increased risk of
post-operative infection (aOR 1.61, 95% CI: 1.06–2.46)
(Table 3).










Age, years, median (IQR) 60 (50–70) 61 (51–71) 60 (49–69) 0.182
Male gender, n (%) 678 (49) 154 (52) 524 (48) 0.294
Race, n (%)
White 1270 (92) 271 (91) 999 (92) 0.295
African-American 67 (5) 19 (6) 48 (4)
Other 47 (3) 8 (3) 39 (4)
Body mass index, kg/m2, median (IQR) 27.2 (24–31) 26.9 (24–32) 27.3 (24–31) 0.969
Operative time, hours, median (IQR) 3.4 (2–5) 4.0 (2–6) 3.3 (2–5) 0.005
Operative blood loss, ml, median (IQR) 150 (40–400) 200 (50–500) 150 (30–400) 0.004
Operative blood transfusion, n (%) 51 (4) 17 (6) 34 (3) 0.037
Malignancy, n (%) 816 (59) 184 (62) 632 (58) 0.270
Diabetes, n (%) 313 (23) 82 (28) 231 (22) 0.020
Open surgery, n (%) 742 (54) 173 (58) 569 (52) 0.083
ASA physical status, n (%)
1 29 (2) 7 (2) 22 (2) 0.019
2 356 (26) 57 (19) 299 (28)
3 914 (66) 210 (71) 704 (65)
4 85 (6) 24 (8) 61 (6)
Smoking status, n (%)
Never 641 (46) 125 (42) 516 (48) 0.191
Current 224 (16) 52 (18) 172 (16)
Former 361 (26) 90 (30) 271 (25)
Unknown 158 (11) 31 (10) 127 (12)
Surgical chemoprophylaxis, n (%)
Ampicillin/sulbactam 869 (63) 165 (55) 704 (65) 0.007
Cefazolin 98 (7) 19 (6) 79 (7)
Cefoxitin 76 (5) 23 (8) 53 (5)
Ciprofloxacin 129 (9) 28 (9) 101 (9)
Piperacillin/tazobactam 78 (6) 25 (8) 53 (5)
Other 134 (10) 38 (13) 96 (9)
Re-dosing non-compliance 485 (35) 126 (42) 359 (33) 0.003
Post-operative infections, n (%) 127 (9) 43 (14) 84 (8) <0.001
Surgical site infections, n (%) 76 (6) 28 (9) 48 (4) 0.001
IQR, interquartile range; SD, standard deviation; ASA, American Society of Anesthesiologists.
*P-values were calculated using Student’s T, Wilcoxon rank-sum, and Pearson v2.
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Risk of surgical site infection
The majority of post-operative infections involved surgical sites
(59.8%, n = 76). Those experiencing a SSI were more likely to
be patients with cancer undergoing open surgery, who experi-
enced longer operative times, increased operative blood loss
and less frequent intra-operative re-dosing of surgical chemo-
prophylaxis in cases where this was indicated. Patients who
smoked had a marginally increased risk of SSI. Pre-operative
hospitalization was associated with a higher risk of SSI (unad-
justed OR 2.24, 95% CI: 1.38–3.64) (Table 2). After adjusting
for other covariates, pre-operative hospitalization was still asso-
ciated with a significantly increased risk of SSI (aOR 1.79, 95%
CI: 1.07–2.97 (Table 3).
Pre-operative hospitalization and antibiotic resistance
Of the patients with post-operative infections, culture sensitiv-
ity data were available for 74.8% (n = 95). Of the 32 patients
with pre-operative hospitalization, 23 had resistant infections.
Meanwhile, 31 of the 63 patients who were not hospitalized
in the year before surgery developed resistant infections.
Table 2 Unadjusted risk of post-operative infection, by type of infection
Any post-operative infection Surgical site infection
OR (95% CI) P* OR (95% CI) P*
Age, years 1.02 (1.01–1.03) 0.002 1.01 (1.00–1.03) 0.162
Male gender 1.68 (1.16–2.44) 0.006 1.96 (1.21–3.17) 0.006
Race 0.403 0.864
White (Reference) 1.00 – 1.00 –
Black 0.45 (0.14–1.45) 0.181 0.79 (0.24–2.58) 0.698
Other 0.89 (0.31–2.53) 0.829 0.75 (0.18–3.16) 0.695
Body mass index, kg/m2 1.01 (0.98–1.03) 0.718 1.00 (0.97–1.04) 0.809
Operative time, hours 1.35 (1.26–1.44) <0.001 1.31 (1.22–1.42) <0.001
Operative blood loss, per 100 ml 1.05 (1.03–1.06) <0.001 1.04 (1.02–1.06) <0.001
Operative blood transfusion 1.08 (0.42–2.77) 0.874 – –
Open surgery 3.22 (2.09–4.94) <0.001 2.73 (1.61–4.64) <0.001
Malignancy 3.27 (2.07–5.18) <0.001 2.74 (1.56–4.80) <0.001
Diabetes 0.87 (0.55–1.37) 0.549 0.91 (0.52–1.60) 0.738
ASA physical status 0.003 0.065
Physical status 1 (Reference) 1.00 – 1.00 –
Physical status 2 0.64 (0.14–2.91) 0.559 0.47 (0.10–2.21) 0.340
Physical status 3 1.58 (0.37–6.77) 0.534 0.83 (0.19–3.59) 0.804
Physical status 4 2.44 (0.52–11.5) 0.261 1.60 (0.32–7.87) 0.564
Smoking status 0.281 0.096
Never smoker (Reference) 1.00 – 1.00 –
Current smoker 1.39 (0.83–2.31) 0.208 1.87 (1.00–3.50) 0.051
Former smoker 1.36 (0.88–2.12) 0.171 1.62 (0.92–2.85) 0.095
Unknown 1.12 (0.61–2.09) 0.710 1.21 (0.54–2.72) 0.640
Surgical chemoprophylaxis <0.001 0.005
Cefazolin (Reference) 1.00 – 1.00 –
Ampicillin/sulbactam 1.18 (0.50–2.80) 0.711 1.10 (0.39–3.16) 0.853
Cefoxitin 4.42 (1.65–11.85) 0.003 2.76 (0.80–9.55) 0.108
Ciprofloxacin 0.88 (0.29–2.71) 0.823 0.56 (0.12–2.56) 0.454
Piperacillin/tazobactam 3.07 (1.12–8.50) 0.031 2.69 (0.78–9.28) 0.118
Other 3.01 (1.17–7.74) 0.022 2.48 (0.87–8.60) 0.084
Re-dosing non-compliance 3.45 (2.36–5.03) <0.001 3.42 (2.11–5.52) <0.001
Pre-operative hospitalization 2.01 (1.36–2.98) <0.001 2.24 (1.38–3.64) 0.001
ASA, American Society of Anesthesiologists; CI, confidence interval; OR, odds ratio.
*P-values were calculated using univariable logistic regression.
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Pre-operative hospitalization was associated with a significantly
higher risk of antibiotic-resistant post-operative infection
(P = 0.035).
Culture sensitivity data were available for 65 patients with
SSIs. Of the 24 patients with SSIs who were hospitalized in the
year before surgery, 19 of these had resistant infections. In
contrast, 20 of the 41 patients with SSIs who were not hospi-
talized in the year before surgery had resistant SSIs. Pre-opera-
tive hospitalization was also significantly associated with an
increased risk of SSIs as a result of microorganisms resistant to
prophylactic antibiotics (P = 0.016).
Finally, for each type of organism cultured from these infec-
tions, we determined whether preoperative hospitalization was
associated with higher rates of antibiotic-resistance (vs. sensi-
tivity). Patients with a pre-operative hospitalization were more
likely to develop an antibiotic-resistant (versus sensitive) infec-
tion with enterococcus (P = 0.001) or lactose-fermenting bac-
teria (P = 0.048) than patients without a pre-operative
hospitalization (Table 4). However, among those with a
staphylococcal infection or infection with gram-negative rods,
pre-operative hospitalization was not associated with a higher
rate of antibiotic-resistant infections (Table 4).
Among patients who developed SSIs, patients with a pre-
operative hospitalization were more likely than those without a
pre-operative hospitalization to develop antibiotic-resistant
infections with enterococcal species (P < 0.001), gram-negative
rods (P < 0.001), or lactose-fermenting bacteria (P = 0.001,
Table 4). There were no significant differences observed in
rates of antibiotic-resistant infections with anaerobic and non-
lactose fermenting gram-negative organisms in those with pre-
operative hospitalization when compared with those without
pre-operative hospitalization (Table 4).
Discussion
In this study, pre-operative hospitalization was associated with
a significantly higher risk of developing a post-operative resis-
tant HAI, including resistant SSIs. These findings contribute to
Table 3 Adjusted risk of post-operative infection, by type of infection
Any post-operative infection Surgical site infection
OR (95% CI) P* OR (95% CI) P*
Age, years 1.01 (0.99–1.03) 0.260 1.00 (0.98–1.02) 0.750
Male gender 1.23 (0.82–1.85) 0.321 1.45 (0.87–2.43) 0.157
Operative time, hours 1.17 (1.07–1.29) 0.001 1.15 (1.03–1.29) 0.014
Operative blood loss (per 100 ml) 1.01 (0.99–1.03) 0.425 1.01 (0.98–1.03) 0.577
Malignancy 1.67 (0.99–2.83) 0.054 1.57 (0.82–3.01) 0.175
ASA physical status 0.299 0.334
Physical status 1 (Reference) 1.00 – 1.00 –
Physical status 2 0.36 (0.07–1.91) 0.231 0.26 (0.05–1.45) 0.126
Physical status 3 0.58 (0.11–2.99) 0.511 0.29 (0.05–1.61) 0.158
Physical status 4 0.70 (0.12–4.20) 0.700 0.44 (0.07–2.88) 0.393
Smoking status 0.955 0.454
Never smoker (Reference) 1.00 – 1.00 –
Current smoker 1.13 (0.65–1.98) 0.659 1.66 (0.85–3.25) 0.140
Former smoker 1.07 (0.66–1.74) 0.777 1.37 (0.75–2.52) 0.305
Unknown 0.95 (0.49–1.83) 0.868 1.04 (0.45–2.44) 0.921
Surgical chemoprophylaxis 0.003 0.044
Cefazolin (Reference) 1.00 – 1.00 –
Cefoxitin 1.43 (0.48–4.22) 0.520 0.83 (0.22–3.18) 0.788
Ampicillin/sulbactam 0.67 (0.26–1.72) 0.411 0.64 (0.21–1.98) 0.439
Ciprofloxacin 0.97 (0.29–3.23) 0.965 0.69 (0.14–3.43) 0.650
Piperacillin/tazobactam 1.56 (1.30–5.13) 0.431 1.32 (0.34–5.03) 0.687
Other 2.38 (0.82–6.87) 0.109 2.46 (0.68–8.90) 0.169
Re-dosing noncompliance 2.15 (1.12–4.13) 0.021 2.47 (1.09–5.58) 0.030
Pre-operative hospitalization 1.61 (1.06–2.46) 0.026 1.79 (1.07–2.97) 0.026
CI, confidence interval; OR, adjusted odds ratio; ASA, American Society of Anesthesiologists.
*P-values were calculated using multivariable logistic regression analyses. Open surgery was not included as a result of collinearity.
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a growing body of literature suggesting that resistant organisms
colonize patients during prior hospitalization.13,14,31,32 MRSA
nasal carriage, for example, is a risk factor for MRSA SSI
whereas testing positive for VRE increases the risk of VRE
infection.33–37 Several previous studies found that patients
admitted from the community with resistant infections were
more likely to have a history of hospitalization, but did not
focus on surgical patients or post-operative infections.8,15,38
Mahajan et al. incidentally found an association between SSI
and patients with cancer hospitalized up to 1 year before gas-
trointestinal surgery, but this association was not examined in
detail and has not previously been demonstrated in patients
undergoing HPB surgery.39
The majority of infections among patients with pre-operative
hospitalization involved microorganisms that were resistant to
surgical chemoprophylaxis, suggesting these patients represent
a high-risk population. Multiple studies agree that patients
with known colonization with resistant organisms or those at a
high risk of post-operative infection should receive broader
prophylactic antibiotic coverage, yet these studies do not sup-
port a specific antibiotic prophylaxis strategy.40,41 For patients
undergoing HPB surgery, adequate prophylactic coverage of
MRSA reduces the incidence MRSA infection, yet vancomycin,
for example, increases the risk of SSI for those not colo-
nized.7,42 Concerning a strategy that expands chemoprophy-
laxis post-operatively, Ren et al.43 demonstrated no difference
in SSI rates within a 30-day post-operative period after HPB
surgery.
In addition to pre-operative hospitalization, our findings
add to the existing body of literature showing that failure to
re-dose surgical chemoprophylaxis intra-operatively (re-dosing
non-compliance) increases the risk for post-operative infection
and SSI.26–29 Current recommendations include instructions to
re-dose prophylactic antibiotics intra-operatively if the dura-
tion of the operation exceeds two half-lives of the antibiotic.
For example, the half-lives of cefoxitin and piperacillin–
tazobactam are 0.7–1.1 and 0.7–1.2 h, which translate into
re-dosing intervals of 2–3 h after the initial dose.21,26,40,44–47
However, despite evidence to support the appropriateness of
current surgical chemoprophylaxis guidelines, there is a sub-
stantial gap between these guidelines and their implementation
in daily practice.48–50 Studies show that antibiotic re-dosing
was found to have the greatest overall non-compliance in SSI
prophylaxis and could reflect a lack of understanding of dosing
practices.26,50 Although our local institutional guidelines reflect
current guidelines, we found that re-dosing non-compliance
remains prevalent in our institution’s chemoprophylaxis prac-
tices; and it is likely that we are not maintaining adequate
antibiotic levels in the circulation of patients who undergo
lengthy surgeries. Re-dosing recommendations may impose an
added task burden in the operating room during busy surg-
eries, especially for antibiotics with relatively short half-lives.
Measures such as improving awareness of current re-dosing
guidelines or procedure-driven prompts for antibiotic selection
in documentation software that include reminders in the oper-
ating room to re-dose antibiotics at specific times may be help-
ful.
We acknowledge several limitations to the present study.
Data contained in some inpatient electronic medical records
are not comprehensive; however, we cross-referenced these
records with scanned paper documents when available to max-
imize accuracy. Some patients who had post-operative infec-
tions may not have sought medical attention or could have
been evaluated outside of our institution. Additionally, we may
not have captured some pre-operative hospitalizations at out-
side hospitals if these were not clearly documented in the clini-
cal notes within our electronic medical record system. There
could also have been some selection bias; pre-operative hospi-
talization is likely a surrogate for severity of illness and comor-
bid conditions, which require therapy and/or inpatient
workup. However, we adjusted for all known covariates that
may account for these differences in illness.
In summary, our results show that pre-operative hospitaliza-
tion is associated with an increased incidence of post-operative
infections with hospital-acquired organisms that are resistant
to standard surgical chemoprophylaxis. In many instances,
Table 4 Organisms resistant to pre-operative antibiotic prophylaxis










Gram-positive cocci 15 (52) 22 (47) 0.488 13 (62) 15 (43) 0.195
Genus Staphylococcus 5 (42) 20 (63) 0.076 4 (40) 14 (58) 0.299
Genus Enterococcus 10 (67) 2 (15) 0.001 9 (75) 1 (11) <0.001
Gram-negative rods 19 (63) 20 (34) 0.053 15 (75) 6 (20) <0.001
Lactose-fermenting 15 (68) 14 (31) 0.048 13 (81) 5 (22) 0.001
Non-lactose-fermenting 4 (57) 6 (38) 0.746 2 (50) 1 (20) 0.290
Anaerobes 1 (25) 0 (0) 1.000 1 (25) 0 (0) 1.000
SSI, surgical-site infection.
*P-values were calculated using Pearson v2 and Fisher’s exact test.
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pre-operative hospitalization cannot be avoided or has
occurred before surgery becomes necessary. In these cases, it is
important to focus on other modifiable risk factors to reduce
the risk of post-operative infection, such as timely re-dosing of
intra-operative antibiotics and broader prophylactic coverage.
For HPB diseases, in particular, many patients require exten-
sive diagnostic or therapeutic procedures prior to surgery.
While inpatient evaluation may improve the efficiency of a
pre-operative workup, this needs to be balanced with the
potentially increased risk of infection. To build on these
results, we plan to conduct cost analyses, analyse a larger series
of patients and focus on identifying high-risk populations that
may benefit from broad-spectrum antibiotic prophylaxis. We
also plan to identify patients who underwent diagnostic and
therapeutic procedures during pre-operative hospitalizations
related to their primary HPB disease and to examine whether
these patients represent a higher risk population when
compared with those hospitalized for other reasons. Ultimately,
our results suggest that patients with a history of hospitaliza-
tion may represent a high-risk group in which current
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